The Limited Times

Now you can see non-English news...

The Oncologists Association recommends: These are the drugs for cancer patients that should be included in the drug basket Israel today

2021-08-30T08:04:26.348Z


The union members rated the 25 most effective drugs for patients, which they will recommend to members of the drug basket committee for 2022, with an emphasis on early treatment of the disease. Oncology warned: "The choice of only 25 drugs - in terms of cutting the meat"


The Association of Oncologists has ranked the 25 most essential, important and effective drugs for cancer patients, which it intends to recommend to include this year in the drug basket.

This year, the association emphasizes early-stage treatment that allows the disease to be cured, along with advanced-stage treatment that allows patients to have a longer life expectancy.

The association's list also includes individualized treatments for patients, depending on the mutations of the tumor, and even treatment for a specific gastrointestinal cancer, in which two people a year, but this type of treatment is different, and offers an efficiency of more than 90%.

The ranking will be submitted by the association's doctors to the drug basket committee, whose members will decide which drugs will enter the basket and be given to patients with public funding starting this January.

The ranking and list do not bind the basket committee, but usually the committee members consider the ranking and recommendations of the cancer experts.

Discussion of the Drug Basket Committee 2021, p

The difficulty of doctors and patients is intensifying this year more than ever, because last year relatively few drugs were introduced for cancer patients, with only 13% of the basket budget earmarked for these drugs, compared to about 40% in previous years.

This has resulted in there being effective and recommended medications that have not entered the medication basket for patients, alongside new contraindications and treatments recommended this year for the first time.

Prof. Gil Bar-Sela, chairman of the Israeli Oncology Association, warns: "Last year, very few anti-cancer drugs were included in the health basket, only 8% of the basket budget was used to treat the disease.

As a result, many patients buy drugs with their own money at high costs or are forced to settle for less effective treatments. "

"The 25 labels we have selected from 82 rankings are defined by us as essential for inclusion in the 2022 health basket. The other drugs on the list are also effective and important, and their reduction to 25 is already a cut in animal meat," he added.

"This is not a list that aims to bargain for the purpose of future reduction. In our opinion, the exclusion of any of the drugs will significantly harm clinically cancer patients in Israel."

In the first place, the drug Tagriso is ranked as an early treatment after surgery for 48 patients with non-small cell lung cancer with certain mutations.

Treatment showed an 83% improvement in patient survival without recurrence of the disease.

In second place is treatment with the immunotherapeutic drug Opedivo for patients with bladder cancer.

This is a treatment given at an early stage and halves the risk of recurrence of the disease.

This drug is also ranked third for esophageal cancer patients.

For them it is intended for complementary treatment after chemotherapy and radiation.

It doubles patient survival from 11 months to 22 months.

In fourth place is the drug Tsentric for the treatment after surgery in patients with non-small cell lung cancer, whose tumor expresses the protein PDL1.

The treatment improved the patients' chance of surviving without the recurrence of the disease by 36%.

In fifth place is the immunotherapeutic drug Kitroda for treatment before and after surgery, for aggressive breast cancer of the type "Triple Gout".

This is a treatment that has improved by up to 84% the chances of patients surviving.

Other notable therapies are the treatment with the drug anharten for gastric cancer and breast cancer for patients whose tumors express the HER2 protein.

Another treatment is one for non-melanoma skin cancer patients with the drug libtio for metastatic or localized tumors that do not respond to radiation.

As recently reported in "Israel Today", one in nine associations and other associations have asked Health Minister Nitzan Horowitz to ensure that the basket committee includes a doctor who specializes in oncology, in light of the fact that drugs for cancer patients form a significant part of the drug basket budget.

The Minister has not yet appointed the composition of the medicine basket committee, but the committee will be required to convene in the next two months, in order to discuss which medicines will enter the medicine basket and be given free of charge to patients starting in January 2022.

Health Minister Nitzan Horowitz (Archive), Oren Ben Hakon

The drug grading process is done by all oncologists in the various fields who have relied on advanced research, efficacy indices of European and American cancer associations and their recommendations, studies published at large conferences, lack of alternatives in the health basket and of course the judgment and experience of attending physicians.

The members of the Association for the Drug Rating Committee this year were Dr. Alona Zer, Dr. Keren Rubinov, Dr. Yonatan Cohen, Dr. Rinat Bernstein, Dr. Einat Shaham-Shmueli, Prof. Gil Bar Sela, Chairman of the Israeli Association To Clinical Oncology and Radiotherapy and Prof. Ido Wolf, Chairman of the National Council for the Prevention, Diagnosis and Treatment of Malignant Diseases.

Source: israelhayom

All news articles on 2021-08-30

You may like

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.